Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.56 | 0.80 | -0.16 | 0.54 |
| FCF Yield | -0.07% | 0.01% | -1.57% | -0.34% |
| EV / EBITDA | 212.61 | -152.08 | -108.69 | -386.94 |
| Quality | ||||
| ROIC | 3.10% | -5.99% | -9.74% | -2.93% |
| Gross Margin | 91.25% | 90.81% | 86.59% | 90.32% |
| Cash Conversion Ratio | -0.24 | -0.02 | 1.21 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 86.46% | 182.73% | 220.46% | 276.39% |
| Free Cash Flow Growth | -813.01% | 100.79% | -439.11% | 83.50% |
| Safety | ||||
| Net Debt / EBITDA | -3.67 | -3.11 | -3.09 | -8.81 |
| Interest Coverage | 2.78 | -4.82 | -8.23 | -1.37 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 0.46 | 0.53 | 0.48 |
| Cash Conversion Cycle | 276.69 | 132.73 | 36.07 | 96.14 |